PUT - SPRINTER OPEN END - BIOGEN IDEC | Delayed Deutsche Boerse AG 13:03:38 03/06/2024 BST | ||
| 6.83 EUR | -1.73% |
|
| 1 month | -10.67% | ||
| 3 months | -4.92% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
BIOGEN INC.
Latest news about BIOGEN INC.
More news
| Date | Price | Change |
|---|---|---|
| 03/06/24 | 6.83 | -1.73% |
| 31/05/24 | 6.95 | -7.58% |
| 30/05/24 | 7.52 | -4.08% |
| 29/05/24 | 7.84 | +2.89% |
| 28/05/24 | 7.62 | +1.74% |
Delayed Quote Deutsche Boerse AG
Last update June 03, 2024 at 01:03 pm
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | BIOGEN INC. |
| Issuer | 
Vontobel
|
| WKN | VU81BV |
| ISIN | DE000VU81BV3 |
| Date issued | 26/06/2023 |
| Strike | 297.3 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 0.92 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 10.18 € |
|---|---|
| Lowest since issue | 0.65 € |
| Spread | 0.03 € |
| Spread % | 0.45% |
Company Profile
Biogen Inc. is one of the world's leaders in the design, manufacturing, and marketing of therapeutic products. Net sales break down by source of income as follows:
- sales of medicines (73,7%): for treating multiple sclerosis, chronic psoriasis in adults, rheumatoid arthritis, cancers, etc.;
- royalties (17,2%) ;
- other (9,1%): primarily revenues from partnership agreements.
Sector
-
Consensus: Biogen Inc.
Sell
Buy
Mean consensus
BUY
Number of Analysts
34
Last Close Price
224.9
USD
Average target price
284.8
USD
Spread / Average Target
+26.60%
- Stock Market
- Certificates
- Certificat
